Anterior pituitary weight, cAMP, cGMP and prolactin levels after combined treatment with estradiol and methylene blue
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
8180149
Knihovny.cz E-zdroje
- MeSH
- adenohypofýza anatomie a histologie účinky léků metabolismus MeSH
- AMP cyklický metabolismus MeSH
- estradiol farmakologie MeSH
- guanosinmonofosfát cyklický metabolismus MeSH
- krysa rodu Rattus MeSH
- lékové interakce MeSH
- methylenová modř farmakologie MeSH
- potkani Wistar MeSH
- prolaktin metabolismus MeSH
- velikost orgánu MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- AMP cyklický MeSH
- estradiol MeSH
- guanosinmonofosfát cyklický MeSH
- methylenová modř MeSH
- prolaktin MeSH
Male rats received estradiol benzoate in a long acting microcrystalline suspension (1 mg/rat i.m., twice a week), methylene blue (MB) 0.5% in the food and the combination of estradiol and MB. After three weeks, MB partially inhibited the growth response of the anterior pituitary to estradiol and it partially inhibited the increase of cAMP content in anterior pituitary. The increase of anterior pituitary cGMP content was not modified by MB, neither the ratio cAMP/cGMP in the anterior pituitary which, however, decreased after estradiol. This decrease was not modified by MB. On the other hand, the prolactin (PRL) increase in the blood after estradiol was inhibited by MB, although the prolactin content in the anterior pituitary was not. Methylene blue alone did not change blood prolactin concentration, but it unexpectedly elevated blood thyroxine levels and this effect was partially inhibited by simultaneous estradiol treatment.
In vivo antiestrogenic activity of mifepristone in the rat